1
|
Wong PC, Seiffert D, Bird JE, Watson CA, Bostwick JS, Giancarli M, Allegretto N, Hua J, Harden D, Guay J, Callejo M, Miller MM, Lawrence RM, Banville J, Guy J, Maxwell BD, Priestley ES, Marinier A, Wexler RR, Bouvier M, Gordon DA, Schumacher WA, Yang J. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci Transl Med 2018; 9:9/371/eaaf5294. [PMID: 28053157 DOI: 10.1126/scitranslmed.aaf5294] [Citation(s) in RCA: 103] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2016] [Accepted: 09/23/2016] [Indexed: 12/21/2022]
Abstract
Antiplatelet agents are proven efficacious treatments for cardiovascular and cerebrovascular diseases. However, the existing drugs are compromised by unwanted and sometimes life-threatening bleeding that limits drug usage or dosage. There is a substantial unmet medical need for an antiplatelet drug with strong efficacy and low bleeding risk. Thrombin is a potent platelet agonist that directly induces platelet activation via the G protein (heterotrimeric guanine nucleotide-binding protein)-coupled protease-activated receptors PAR1 and PAR4. A PAR1 antagonist is approved for clinical use, but its use is limited by a substantial bleeding risk. Conversely, the potential of PAR4 as an antiplatelet target has not been well characterized. Using anti-PAR4 antibodies, we demonstrated a low bleeding risk and an effective antithrombotic profile with PAR4 inhibition in guinea pigs. Subsequently, high-throughput screening and an extensive medicinal chemistry effort resulted in the discovery of BMS-986120, an orally active, selective, and reversible PAR4 antagonist. In a cynomolgus monkey arterial thrombosis model, BMS-986120 demonstrated potent and highly efficacious antithrombotic activity. BMS-986120 also exhibited a low bleeding liability and a markedly wider therapeutic window compared to the standard antiplatelet agent clopidogrel tested in the same nonhuman primate model. These preclinical findings define the biological role of PAR4 in mediating platelet aggregation. In addition, they indicate that targeting PAR4 is an attractive antiplatelet strategy with the potential to treat patients at a high risk of atherothrombosis with superior safety compared with the current standard of care.
Collapse
Affiliation(s)
- Pancras C Wong
- Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534, USA.
| | - Dietmar Seiffert
- Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, USA
| | - J Eileen Bird
- Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534, USA
| | - Carol A Watson
- Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534, USA
| | - Jeffrey S Bostwick
- Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534, USA
| | - Mary Giancarli
- Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534, USA
| | - Nick Allegretto
- Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534, USA
| | - Ji Hua
- Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534, USA
| | - David Harden
- Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534, USA
| | - Jocelyne Guay
- Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Quebec H3C 3J7, Canada
| | - Mario Callejo
- Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Quebec H3C 3J7, Canada
| | - Michael M Miller
- Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, USA
| | | | - Jacques Banville
- Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Quebec H3C 3J7, Canada
| | - Julia Guy
- Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Quebec H3C 3J7, Canada
| | - Brad D Maxwell
- Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, USA
| | - E Scott Priestley
- Bristol-Myers Squibb Company, 350 Carter Road, Hopewell, NJ 08540, USA
| | - Anne Marinier
- Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Quebec H3C 3J7, Canada
| | - Ruth R Wexler
- Bristol-Myers Squibb Company, 350 Carter Road, Hopewell, NJ 08540, USA
| | - Michel Bouvier
- Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Quebec H3C 3J7, Canada.,Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Quebec H3C 3J7, Canada
| | - David A Gordon
- Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534, USA
| | - William A Schumacher
- Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534, USA
| | - Jing Yang
- Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08534, USA
| |
Collapse
|
2
|
Ahmad S, Madsen CS, Stein PD, Janovitz E, Huang C, Ngu K, Bisaha S, Kennedy LJ, Chen BC, Zhao R, Sitkoff D, Monshizadegan H, Yin X, Ryan CS, Zhang R, Giancarli M, Bird E, Chang M, Chen X, Setters R, Search D, Zhuang S, Nguyen-Tran V, Cuff CA, Harrity T, Darienzo CJ, Li T, Reeves RA, Blanar MA, Barrish JC, Zahler R, Robl JA. (3R,5S,E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1H-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic Acid (BMS-644950): A Rationally Designed Orally Efficacious 3-Hydroxy-3-methylglutaryl Coenzyme-A Reductase Inhibitor with Reduced Myotoxicity Potential. J Med Chem 2008; 51:2722-33. [DOI: 10.1021/jm800001n] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Saleem Ahmad
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Cort S. Madsen
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Philip D. Stein
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Evan Janovitz
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Christine Huang
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Khehyong Ngu
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Sharon Bisaha
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Lawrence J. Kennedy
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Bang-Chi Chen
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Rulin Zhao
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Doree Sitkoff
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Hossain Monshizadegan
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Xiaohong Yin
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Carol S. Ryan
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Rongan Zhang
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Mary Giancarli
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Eileen Bird
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Ming Chang
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Xing Chen
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Robert Setters
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Debra Search
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Shaobin Zhuang
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Van Nguyen-Tran
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Carolyn A. Cuff
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Thomas Harrity
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Celia J. Darienzo
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Tong Li
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Richard A. Reeves
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Michael A. Blanar
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Joel C. Barrish
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Robert Zahler
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| | - Jeffrey A. Robl
- Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543
| |
Collapse
|
3
|
Kowala MC, Murugesan N, Tellew J, Carlson K, Monshizadegan H, Ryan C, Gu Z, Kane B, Fadnis L, Baska RA, Beyer S, Arthur S, Dickinson K, Zhang D, Perrone M, Ferrer P, Giancarli M, Baumann J, Bird E, Panchal B, Yang Y, Trippodo N, Barrish J, Macor JE. Novel Dual Action AT1 and ETA Receptor Antagonists Reduce Blood Pressure in Experimental Hypertension. J Pharmacol Exp Ther 2004; 309:275-84. [PMID: 14718594 DOI: 10.1124/jpet.103.055855] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Angiotensin II and endothelin-1 activate their respective AT(1) and ET(A) receptors on vascular smooth muscle cells, producing vasoconstriction, and both peptides are implicated in the pathogenesis of essential hypertension. Angiotensin II potentiates the production of endothelin, and conversely endothelin augments the synthesis of angiotensin II. Both AT(1) and ET(A) receptor antagonists lower blood pressure in hypertensive patients; thus, a combination AT(1)/ET(A) receptor antagonist may have greater efficacy and broader utility compared with each drug alone. By rational drug design a biphenyl ET(A) receptor blocker was modified to acquire AT(1) receptor antagonism. These compounds (C and D) decreased Sar-Ile-Angiotensin II binding to AT(1) receptors and endothelin-1 binding to ET(A) receptors, and compound C inhibited angiotensin II- and endothelin-1-mediated Ca(2+) transients. In rats compounds C and D reduced blood pressure elevations caused by intravenous infusion of angiotensin II or big endothelin-1. Compound C decreased blood pressure in Na(+)-depleted spontaneously hypertensive rats and in rats with mineralocorticoid hypertension. Compound D was more efficacious than AT(1) receptor antagonists at reducing blood pressure in spontaneously hypertensive rats, and its superiority was likely due to its partial blockade of ET(A) receptors. Therefore compounds C and D are novel agents for treating a broad spectrum of patients with essential hypertension and other cardiovascular diseases.
Collapse
Affiliation(s)
- Mark C Kowala
- Department of Metabolic and Cardiovascular Drug Discovery 025-289, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Murugesan N, Gu Z, Stein PD, Bisaha S, Spergel S, Girotra R, Lee VG, Lloyd J, Misra RN, Schmidt J, Mathur A, Stratton L, Kelly YF, Bird E, Waldron T, Liu EC, Zhang R, Lee H, Serafino R, Abboa-Offei B, Mathers P, Giancarli M, Seymour AA, Webb ML, Hunt JT. Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308). J Med Chem 1998; 41:5198-218. [PMID: 9857090 DOI: 10.1021/jm970872k] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Substitution at the ortho position of N-(3,4-dimethyl-5-isoxazolyl) benzenesulfonamide led to the identification of the biphenylsulfonamides as a novel series of endothelin-A (ETA) selective antagonists. Appropriate substitutions on the pendant phenyl ring led to improved binding as well as functional activity. A hydrophobic group such as isobutyl or isopropoxyl was found to be optimal at the 4'-position. Introduction of an amino group at the 2'-position also led to improved analogues. Combination of the optimal 4'-isobutyl substituent with the 2'-amino function afforded an analogue (20, BMS-187308) with improved ETA binding affinity and functional activity. Compound 20 also has good oral activity in inhibiting the pressor effect caused by an ET-1 infusion in rats. Doses of 10 and 30 micromol/kg iv 20 attenuated the pressor responses due to the administration of exogenous ET-1 to conscious monkeys, indicating that the compound inhibits the in vivo activity of endothelin-1 in nonhuman primates.
Collapse
Affiliation(s)
- N Murugesan
- Departments of Chemistry, Cardiovascular Agents, Cardiovascular Biochemistry, and Pharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|